well as protein immunoexpression 10, [12] [13] [14] and Epstein-Barr virus (EBV) association, [15] [16] [17] have also been identified as prognostic factors in several studies.
However, when sufficiently intensive treatment for advanced stages is employed, adverse prognostic factors tend to disappear. 9 Thus, the identification of clinical and biological factors that allow discrimination of patients who may undergo a reduction in treatment intensity is a current goal to reduce late effects in HL.
The objective of this single-center study was to identify pretreatment characteristics that could be useful for adjustment of risk stratification in children with HL. 
Materials and methods

Patients
Staging and laboratory evaluation
All patients were assessed before starting therapy by means of clinical history, complete physical examination, blood counts and biochemical profile, chest x-ray films, computed tomography of chest and abdomen and unilateral bone marrow biopsy. Staging followed the Ann-Arbor classification system. 19 B symptoms were characterized by fever ≥ 38 ºC for at least 3 consecutive days, night sweats and loss of weight. Disease risk was classified as favorable (I, IIA, IIIA) or unfavorable (IIB, IIIB, IV). Anemia was defined as hemoglobin < 13 g/dL (< 11.5 g/dL for female patients in reproductive age). Lactate dehydrogenase (LDH) and erythrocyte sedimentation rate (ESR) were considered high when higher than 500 IU/L and 40 mm/h, respectively.
Treatment
All patients received doxorubicin-containing chemotherapy. Alternating Adriamycin TM , bleomycin, vinblastine and dacarbazine/vincristine, procarbazine, prednisone and Adriamycin TM (ABVD/OPPA) were administered to 33 children (47.8%) until 1996 and ABVD alone, to 36 children (52.2%) after 1996, respectively. 20, 21 Children in the favorable risk group were treated with three cycles of chemotherapy, while those in the unfavorable risk group received six cycles. Low-dose involved-field radiotherapy was administered to all patients, except for one patient with stage IA, at the end of chemotherapy protocol (15 Gy for patients that achieved complete response and 25 Gy for those with bulky disease at presentation or local residual disease at the end of chemotherapy). 
Variables analyzed as potential prognostic factors
Statistical analysis
Associations between categorical variables were tested using two-tailed Pearson's chi-square and Fisher's exact tests. Significance was set at p < 0.05. Event-free survival (EFS) was estimated as the interval (in months) from diagnosis to relapse or death by any cause or, alternatively, to the last follow-up. Overall survival (OS) refers to the lapse (in months) from diagnosis to death or last follow-up. Survival distributions were estimated according to the Kaplan-Meier method, 22 and differences were assessed by the log-rank test. Multivariate analysis using Cox proportional hazard regression 23 was performed to determine the independent prognostic factors influencing EFS. Data were analyzed with SPSS v.13.0.
Results
Clinical and demographic characteristics at presentation
Of the 69 patients included in this study, 49 (71%) were male (M:F 2.45:1). Ages ranged from 2 to 18 years Table 1 ).
The number of IAA varied from one to eight (median two). The former results suggested that the number of IAA could be used to improve the risk stratification system. Thus, the original risk groups were adjusted by the number of IAA: cases with unfavorable disease and < four IAA were reclassified as "favorable disease" (except for extranodal disease that was maintained as unfavorable), and children with favorable disease and ≥ four IAA were reclassified to the unfavorable disease group. With this reallocation, only one of the 22 patients initially in the favorable risk group was reallocated to the adjusted unfavorable risk group; however, of the 47 patients originally in the unfavorable risk group, 31 (66%) were reallocated to the favorable risk B symptoms = fever ≥ 38 ºC for at least 3 consecutive days, night sweats and loss of weight.
reallocated from the original unfavorable risk group to the favorable risk group based on the number of IAA exhibited late effects (p = 0.005)
Discussion
In respect to clinical outcome, our results with a risk-adapted, homogeneously treated group of patients achieved survival rates comparable to those obtained in developed countries 2, 5, 24, 25 and in the most developed region of Brazil. 21 The late effects were also similar to those described in other studies that treated children with the same protocols. [1] [2] [3] [4] [5] [6] With the current risk-stratified treatment for HL, long-term disease-free survivals (DFS)
were 85 to 100% in patients with early-stage disease, and more than 60% in those with advanced disease. 26 The
German Hodgkin Study Group showed an improvement of survival for patients with advanced stages when more intensive treatments were applied. 4 However, it is well known that higher survival rates are accompanied by late effects of treatment, mostly in patients treated during childhood. 5 For example, the excellent results reached in high stages by the German Hodgkin Study Group were associated with a higher frequency of secondary acute myeloid leukemia/myelodysplastic syndrome. 4 Thus, it is accepted that the challenge today in HL treatment is to minimize late toxicity without compromising the excellent survival rates. It was showed that children with more than four IAA had a 6.4-fold increased risk of unfavorable outcome.
The results agree with those of Vassilakopoulos et al.,
who showed a significant influence of this variable in DFS prediction in adolescents and adults with advanced-stage disease. 10 Conversely, a previous study on childhood HL did not show a significant effect of IAA on DFS. 27 The discordance between the results of this current study and those reported by Oguz et al. 27 might be due to the fact that the latter study only considered the number of involved nodal sites, suggesting that the number of total involved sites (nodal and extranodal) may be a better predictor of prognosis in pediatric HL.
The number of IAA may be a surrogate indicator of tumor burden, a strong adverse prognostic factor
for HL albeit a difficult variable to quantify or even estimate. [27] [28] [29] [30] [31] Staging is unable to predict tumor burden with more accuracy because it does not consider the number of affected anatomic sites. For example, a stage IIA patient with cervical and axillary nodes, both on the same body side, would have a lower tumor burden than another patient with no symptoms and cervical and axillary bilateral involvement, who would also be staged as IIA. Therefore, it is possible that some children with advanced-stage disease are overtreated. 9 The results of this study indicate that a subgroup of patients with better 
